ALAUNOS THERAPEUTICS INC (TCRT)

US98973P2002 - Common Stock

1.88  +0.02 (+1.08%)

After market: 1.83 -0.05 (-2.66%)

Fundamental Rating

2

Taking everything into account, TCRT scores 2 out of 10 in our fundamental rating. TCRT was compared to 592 industry peers in the Biotechnology industry. TCRT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TCRT is valued expensive and it does not seem to be growing.



0

1. Profitability

1.1 Basic Checks

TCRT had negative earnings in the past year.
TCRT had a negative operating cash flow in the past year.
In the past 5 years TCRT reported 4 times negative net income.
In the past 5 years TCRT always reported negative operating cash flow.

1.2 Ratios

TCRT has a worse Return On Assets (-187.94%) than 89.97% of its industry peers.
Looking at the Return On Equity, with a value of -262.30%, TCRT is doing worse than 73.98% of the companies in the same industry.
Industry RankSector Rank
ROA -187.94%
ROE -262.3%
ROIC N/A
ROA(3y)-65.26%
ROA(5y)-31.89%
ROE(3y)-99.26%
ROE(5y)-52.29%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TCRT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

5

2. Health

2.1 Basic Checks

TCRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TCRT has more shares outstanding
TCRT has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, TCRT has a worse debt to assets ratio.

2.2 Solvency

Based on the Altman-Z score of -67.48, we must say that TCRT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -67.48, TCRT is doing worse than 97.11% of the companies in the same industry.
There is no outstanding debt for TCRT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -67.48
ROIC/WACCN/A
WACC10.29%

2.3 Liquidity

A Current Ratio of 2.74 indicates that TCRT has no problem at all paying its short term obligations.
TCRT has a worse Current ratio (2.74) than 71.43% of its industry peers.
A Quick Ratio of 2.74 indicates that TCRT has no problem at all paying its short term obligations.
The Quick ratio of TCRT (2.74) is worse than 69.22% of its industry peers.
Industry RankSector Rank
Current Ratio 2.74
Quick Ratio 2.74

1

3. Growth

3.1 Past

TCRT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1163.16%.
TCRT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -99.66%.
The Revenue for TCRT have been decreasing by -14.50% on average. This is quite bad
EPS 1Y (TTM)-1163.16%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-1400%
Revenue 1Y (TTM)-99.66%
Revenue growth 3YN/A
Revenue growth 5Y-14.5%
Revenue growth Q2Q-100%

3.2 Future

Based on estimates for the next years, TCRT will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.90% on average per year.
The Revenue is expected to decrease by -14.87% on average over the next years. This is quite bad
EPS Next Y-210.14%
EPS Next 2Y8.3%
EPS Next 3Y47.14%
EPS Next 5Y12.9%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y623.82%
Revenue Next 5Y-14.87%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TCRT. In the last year negative earnings were reported.
Also next year TCRT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

TCRT's earnings are expected to grow with 47.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.3%
EPS Next 3Y47.14%

0

5. Dividend

5.1 Amount

TCRT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ALAUNOS THERAPEUTICS INC

NASDAQ:TCRT (3/28/2024, 3:21:24 PM)

After market: 1.83 -0.05 (-2.66%)

1.88

+0.02 (+1.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap30.16M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -187.94%
ROE -262.3%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.74
Quick Ratio 2.74
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-1163.16%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-210.14%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-99.66%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y